Dr. Stefania Nicoli, PhD, Associate Professor at Yale School of Medicine, has built a distinguished career at the intersection of genetics, cardiovascular biology, and RNA biology. With joint appointments in the Departments of Internal Medicine (Cardiovascular Medicine) and Genetics, she also directs the Yale Zebrafish Phenotyping Core for Precision Medicine and co-directs the Yale Cardiovascular Research Center. This year, she was elected as a Fellow of the American Heart Association (FAHA), an honor that recognizes her outstanding scientific achievements and her continued commitment to advancing cardiovascular research.
Dr. Nicoli received her bachelor’s degree in Pharmaceutical Biotechnology from the University of Milan and a PhD in Biomedical Biotechnology from the University of Brescia. Her postdoctoral research at the University of Massachusetts Medical School focused on microRNAs and vascular development, a focus that has since shaped her career. Since joining Yale in 2012, she has pioneered the use of zebrafish models to investigate the regulatory functions of non-coding RNAs in vivo.
Dr. Nicoli emphasized the unique advantages of using zebrafish in developmental biology. “Zebrafish embryos develop externally, so you can expose them to environmental perturbations from the first cell division,” she explained. This makes them a powerful model for understanding how cells adapt or fail to adapt to environmental challenges. Her recent work delves into how mRNA can be harnessed to engineer cellular resilience, particularly in response to age-related changes in the extracellular matrix. “During aging or in disease, the extracellular matrix becomes stiffer and more complex,” she said. “We’re trying to understand how cells respond to that and whether we can use mRNA therapeutics to help them respond better.” Her lab’s research has uncovered mechanisms by which cells might “ignore” or modulate their responses to stiffened environments, a discovery with exciting implications for treating inflammation and degenerative diseases.
Dr. Nicoli shared that the recognition from the American Heart Association (AHA) was especially meaningful in a time of uncertainty for the scientific community. “It’s been a tough year for scientists,” she reflected. “Being recognized by a leading society like the AHA gives us renewed motivation. It reminds us that our work matters.” Beyond personal achievement, she views her Fellow of the AHA designation as a commitment to outreach. “The AHA is deeply engaged in educating the public and fostering collaboration. As a Fellow, it’s my responsibility to contribute to those efforts—not just in the lab, but in society at large.”
Mentorship has played a central role throughout Dr. Nicoli’s career, both as a mentee and now as a mentor. “When I was starting out, mentorship meant being given the opportunity to grow,” she said. “But once I became a PI, I realized mentorship also means supporting people as human beings.” She views mentorship as a holistic investment: “If you can nurture both the scientist and the individual, that’s the most meaningful accomplishment.”
Dr. Nicoli draws strength from small victories: “It’s the daily progress. The experiments, the curiosity, the little steps forward—that keeps me going. We can’t always think six months or five years ahead. We have to stay present.” She also emphasized the enduring nature of science. “Science doesn’t stop with us. No matter the obstacles, the pursuit of knowledge continues.”
Dr. Nicoli encouraged young scientists and junior PIs to keep doing their best, reminding them that despite the challenges, they have the privilege of working at excellent institutions, collaborating with brilliant colleagues, and pursuing meaningful scientific work. “I would emphasize the importance of seeking support. Don’t isolate yourself. It’s natural to feel worried, but sharing those concerns is the first step toward coping. Stay connected, and don’t lose sight of the passion that brought you here in the first place—science.”